证券代码：688203 证券简称：海正生材 公告编号：2024-38 浙江海正生物材料股份有限公司 收到控股股东关于董事候选人推荐函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二○二四年十月一日 公司将按照相关法律法规要求尽快完成董事补选和董事长选举工作。 特此公告。 浙江海正生物材料股份有限公司董事会 2024 年 9 月 30 日，公司收到控股股东浙江海正集团有限公司《关于推荐郑 柏超为浙江海正生物材料股份有限公司董事候选人的函》。浙江海正集团有限公 司推荐郑柏超先生为公司第七届董事会董事候选人，并建议推选郑柏超先生为董 事长候选人，郑柏超先生简历如下： 郑柏超：男，1979 年 6 月，本科，高级经济师。曾任椒江区财政局经济建设 科副科长；椒江区政府性项目投融资管理中心主任；台州市椒江区国有资产经营 有限公司副董事长、副总经理；台州市椒江区国有资本运营集团有限公司董事、 副总经理。现任台州市椒江区国有资本运营集团有限公司董事、总经理，浙江海 正集团有限公司董事及代理董事长，浙江海正药业股份有限公司董事及代 ...

Investment Rating - The investment rating for the company is "Hold" with a downward adjustment [5]. Core Insights - The company reported a revenue of 431 million yuan for the first half of 2024, representing a year-on-year increase of 29.19%, and a net profit of 25 million yuan, up 27.05% year-on-year [1]. - The demand for polylactic acid (PLA) is on the rise globally, with the company's sales and profits steadily increasing. The company holds a market share exceeding that of well-known European and American competitors, maintaining its position as the leading domestic player [2]. - The growth in sales is attributed to the performance advantages of PLA materials, which have opened up new market demands, particularly in sectors like 3D printing and transparent packaging [3]. Financial Performance Summary - For the first half of 2024, the company achieved a production volume of 24,700 tons of pure PLA, with a sales rate of 98.86%, corresponding to sales of 24,400 tons. The sales of PLA resin increased by 48.22% year-on-year, with domestic sales growing by 35% and international sales by 140% [2]. - The company’s revenue projections for 2024-2026 are updated to 916 million, 1.136 billion, and 1.619 billion yuan respectively, with net profits of 52 million, 68 million, and 102 million yuan respectively [3][4]. - The earnings per share (EPS) are projected to be 0.26, 0.34, and 0.50 yuan for 2024, 2025, and 2026 respectively [4]. Market Dynamics - The demand for PLA is driven by regulatory policies against plastic, and the material's inherent performance advantages are becoming a new driving force for industry development [3]. - The 3D printing materials segment saw a significant increase of 117% year-on-year in the first half of 2024, driven by technological innovations and strong market demand [3]. - The company is optimizing material performance to increase procurement shares from major existing customers, even in markets where overall demand has not significantly increased [3].

关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688203 证券简称：海正生材 公告编号：2024-37 一、 回购股份的基本情况 浙江海正生物材料股份有限公司 浙江海正生物材料股份有限公司（以下简称"公司"）于2024年8月28日召开第 七届董事会第十次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案 的议案》，同意公司以自有资金通过上海证券交易所系统以集中竞价交易方式回购 公司已发行的部分人民币普通股（A股）股票，拟在未来适宜时机用于公司股权激 励或员工持股计划。公司本次回购价格不超过人民币12.00元/股（含），回购资金 总额不低于人民币2,000万元（含），不超过人民币3,000万元（含），本次回购期 限自公司董事会审议通过本次回购方案之日起不超过12个月。具体内容详见公司 分别于2024年8月29日、2024年9月3日在上海证券交易所网站（www.sse.com.cn） 披露的《浙江海正生物材料股份有限公司关于以集中竞价交易方式回购股份 ...

证券代码：688203 证券简称：海正生材 公告编号：2024-35 浙江海正生物材料股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第七届董事会第十次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，具体内容详见公司于 2024 年 8 月 29 日在上海证券交易所 网站（www.sse.com.cn）披露的《浙江海正生物材料股份有限公司关于以集中竞 价交易方式回购股份方案的公告》（公告编号：2024-34）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7号——回购股份》等相关规定，现将公司第七届董事会第十次会议决议公告的 前一个交易日（即2024年8月28日）登记在册的前十名股东和前十名无限售条件 股东的名称、持股数量及持股比例情况公告如下： | 序号 | 股东名称 | 持股数量 （股） | 占总股本比 例（%） ...

证券代码：688203 证券简称：海正生材 公告编号：2024-34 浙江海正生物材料股份有限公司 关于以集中竞价方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关风险提示： 1、若在回购期限内，公司股票价格持续超出回购价格上限，可能带来本次回 购方案无法顺利实施或只能部分实施的风险。 2、若发生对公司股票交易价格产生重大影响的重大事项，或公司生产经营、 财务情况、外部客观情况发生重大变化，或其他导致公司董事会提请终止本次回购 方案的事项发生，则可能带来本次回购方案无法顺利实施或者根据相关规定变更 或终止本次回购方案的风险。 3、公司本次回购股份拟在未来适宜时机用于公司股权激励或员工持股计划， 若公司未能在规定的期限内实施上述用途，则可能带来全部或部分已回购未转让 股份予以注销的风险。 ● 回购股份金额：不低于人民币 2,000 万元（含），不超过人民币 3,000 万元（含）。 ● 回购股份资金来源：公司自有资金。 ● 回购股份用途：本次回购的股份拟用于公司股权激励或员工持股 ...

单位：吨 | 期间 | 产品 | 产能 | 产量 | 产能利用率 | 产销率 | | --- | --- | --- | --- | --- | --- | | 2024 年 | 纯聚乳酸 | 30,000.00 | 24,715.14 | 82.38% | 98.86% | | 上半年 | | | | | | | 2023 年度 | 纯聚乳酸 | 50,000.00 | 39,478.55 | 78.96% | 95.12% | | 2022 年度 | 纯聚乳酸 | 40,000.00 | 25,866.80 | 64.67% | 100.43% | 浙江海正生物材料股份有限公司 2024 年度"提质增效重回报"行动方案 为贯彻落实关于开展科创板上市公司"提质增效重回报"专项行动的倡议， 落实以投资者为本的理念，推动上市公司持续优化经营、规范治理和积极回报投 资者，大力提高上市公司质量，助力信心提振、资本市场稳定和经济高质量发展 的精神要求，浙江海正生物材料股份有限公司（以下简称"公司"）特制定 2024 年度"提质增效重回报"行动方案，以进一步提升公司经营效率，强化市场竞争 力，保障投资者权益，稳定股价， ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年 8 月 28 日，浙江海正生物材料股份有限公司（以下简称"公司"） 董事会收到公司董事长沈星虎先生提交的书面辞职报告，沈星虎先生因个人原因， 请求辞去公司第七届董事会董事、董事长及董事会审计委员会委员、董事会战略 委员会召集人职务，同时不再担任公司法定代表人。辞职后，沈星虎先生不在公 司担任任何职务。 根据《公司法》、《公司章程》等有关规定，沈星虎先生辞职未导致公司董事 会成员低于法定最低人数，不会影响公司董事会的正常运作及公司经营管理工作 的正常进行，辞职报告自送达董事会时生效。 证券代码：688203 证券简称：海正生材 公告编号：2024-31 浙江海正生物材料股份有限公司 关于董事长辞职的公告 特此公告。 浙江海正生物材料股份有限公司董事会 二○二四年八月二十九日 在选举产生新任董事长前，根据《公司章程》规定，全体董事一致推举董事 兼总经理陈志明先生代理履行董事长及法定代表人的职责。公司将按照相关法律 法规要求尽快完成董事补选和董事长选举工作。 ...

证券代码：688203 证券简称：海正生材 公告编号：2024-32 浙江海正生物材料股份有限公司 第七届董事会第十次会议决议公告 一、审议通过《关于以集中竞价交易方式回购公司股份方案的议案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）第七届董事会第十次 会议于 2024 年 8 月 28 日上午以通讯方式召开，会议通知已于 2024 年 8 月 22 日以电子邮件方式送达全体董事。会议应出席董事 8 人，实际出席董事 8 人。本 次会议的召集、召开程序和方式符合《公司法》和《公司章程》的有关规定，会 议决议合法、有效。本次会议由董事兼总经理陈志明先生主持，经审议，与会董 事以通讯方式通过如下决议： 具体内容详见公司于同日在上海证券交易所网站(www.sse.com.cn)披露的 《浙江海正生物材料股份有限公司2024年度"提质增效重回报"行动方案》。 特此公告。 浙江海正生物材料股份有限公司董事会 二○二四年八月二十九日 2 基于对公司未来发展前景的信心和对公司价值的 ...

证券代码：688203 证券简称：海正生材 公告编号：2024-33 浙江海正生物材料股份有限公司 第七届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）第七届监事会第八次 会议于 2024 年 8 月 28 日上午以通讯方式召开，会议通知已于 2024 年 8 月 22 日以电子邮件方式送达全体监事。会议应出席监事 3 人，实际出席监事 3 人，会 议由监事会主席徐伟先生召集并主持。本次会议的召集、召开程序和方式符合《公 司法》和《公司章程》的有关规定，会议决议合法、有效。经审议，与会监事以 通讯方式审议通过公司《关于以集中竞价交易方式回购公司股份方案的议案》。 公司使用自有资金通过集中竞价交易方式回购公司股份，回购股份用于公司 股权激励或员工持股计划。回购价格不超过人民币 12.00 元/股（含），回购资 金总额不低于人民币 2,000 万元（含），不超过人民币 3,000 万元（含），具体 回购股份的数量以回购期满时实际回购的股份数量为准。回购 ...

Financial Performance - The company's operating revenue for the first half of 2024 reached CNY 430,942,201.36, representing a 29.19% increase compared to CNY 333,560,960.24 in the same period last year[13]. - The net profit attributable to shareholders of the listed company was CNY 25,100,271.36, up 27.05% from CNY 19,755,767.54 year-on-year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20,989,973.29, reflecting a 19.04% increase from CNY 17,632,803.50 in the previous year[13]. - Revenue for the reporting period reached CNY 4.31 billion, reflecting a year-on-year growth of 29.19%, driven by a 48.22% increase in resin sales[17]. - The net profit attributable to shareholders increased by 27.05% due to higher revenue and increased government subsidies[17]. - The company achieved operating revenue of 431 million yuan, a year-on-year increase of 29.19%, with resin sales growing by 48.22%[36]. - Domestic sales increased by 35%, while overseas sales surged by 140% during the reporting period[36]. - The company reported a significant decrease in net cash flow from operating activities, down 91.75% compared to the previous year, primarily due to increased operational procurement payments[66]. Research and Development - The company’s R&D expenditure as a percentage of operating income decreased to 3.34%, down 0.42 percentage points year-on-year[16]. - Total R&D investment reached ¥14,406,673.67, an increase of 14.85% compared to ¥12,543,983.89 in the same period last year[40]. - The company has a unique R&D platform that supports the transition from laboratory to large-scale commercial production, ensuring a robust innovation pipeline[35]. - The company obtained 2 new authorized invention patents during the reporting period, including methods for anti-static modified polylactic acid and polylactic acid-polyvinyl alcohol graft copolymer preparation[39]. - The company has a cumulative total of 58 patent applications, with 43 patents granted[39]. - The company has developed over 10 major PLA grades and more than 30 sub-brands, covering various customer requirements in physical and mechanical properties[47]. Production and Operations - The company specializes in the research, production, and sales of polylactic acid (PLA), mastering key technologies for both pure PLA manufacturing and composite modification, achieving large-scale production[23]. - The company has developed a full-process commercial production line for PLA, covering the entire industrialization process from lactic acid to PLA, ensuring high optical purity and production yield[23]. - The company's production capacity utilization reached 90% in the first half of 2024, following the launch of a 30,000 tons/year polylactic acid production line in late 2020 and a 20,000 tons/year line in June 2023[35]. - The company employs a "sales-driven production" model, ensuring that procurement and production are aligned with sales forecasts to maintain optimal inventory levels[30]. - The production model allows for flexibility in meeting customer orders, with the option for outsourcing to meet specific product requirements[31]. Market Position and Strategy - The company holds a leading position in the domestic market with a market share exceeding that of well-known European and American competitors, solidifying its status as the industry leader in China[35]. - The company aims to expand its market presence in biodegradable materials, addressing the growing demand for environmentally friendly alternatives to traditional plastics[23]. - The company is positioned to benefit from increasing consumer awareness of environmental issues and the implementation of new pollution control policies globally[23]. Environmental and Compliance - The company has established a set of air pollution control facilities with a processing capacity of 2,000 cubic meters per hour[81]. - The company has a wastewater treatment system with a processing capacity of 300 tons per day[81]. - The company has implemented an emergency response plan for environmental incidents, filed with the local environmental authority[81]. - The company has increased its investment in energy conservation and emission reduction, completing multiple energy-saving renovation projects to lower energy consumption[84]. - The company actively responded to the national "carbon neutrality" strategy by optimizing production processes and updating equipment, maintaining stable unit energy consumption and reducing greenhouse gas emissions[85]. Financial Position - The total assets at the end of the reporting period were CNY 2,045,191,279.09, showing a slight decrease of 0.26% from CNY 2,050,517,959.42 at the end of the previous year[15]. - The net assets attributable to shareholders of the listed company increased to CNY 1,490,151,099.08, a 0.60% rise from CNY 1,481,265,073.16 at the end of the previous year[15]. - The company's cash and cash equivalents decreased by 30.41% year-on-year, attributed to increased investments in fundraising projects[67]. - The company’s total liabilities decreased to ¥76,406,795.84, down 27.33% from ¥105,146,616.00, primarily due to repayment of maturing bank loans[69]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its IPO, ensuring shareholder stability[86]. - The company has established a commitment to maintain compliance with laws and regulations regarding shareholding and transfer by its directors and senior management[90]. - The company will ensure compliance with relevant laws and regulations regarding shareholding changes and will report any changes in shareholding status in a timely manner[93]. - The company has committed to compensating investors for any losses incurred due to false statements or omissions in the prospectus, as per regulatory requirements[103]. Risks and Challenges - The company faces risks from concentrated suppliers, as any adverse changes could impact supply and increase costs[59]. - The company is exposed to raw material price fluctuations, particularly for high-purity lactic acid, which could affect production costs and profitability[59]. - Increased competition in the PLA market may arise from both domestic and international players, potentially leading to price declines[60]. - The company faces risks related to environmental protection compliance, which may increase operational costs due to stricter regulations[63].